Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare)

Bode, Bruce W.; Chaykin, Louis; Sussman, Allen; Warren, Mark; Niemeyer, Marcus; Rabøl, Rasmus; Rodbard, Helena W.

doi:10.4158/ep13411.or

Cited by 26 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A more concentrated form of IDeg (200 U/mL) has been also developed and tested in two studies, ie, BEGIN Low Volume 29 and BEGIN Compare. 30 BEGIN Low Volume compared IDeg (200 IU/mL) versus IGla and reported results similar to those of other trials in insulin-naïve T2DM patients, with equal efficacy in terms of HbA 1c reduction and a comparable hypoglycemia rate. 29 The BEGIN Compare study compared IDeg 200 IU/mL with IDeg 100 IU/mL, and the results showed comparable efficacy between the groups with regard to glycemic control and hypoglycemia rates.…”

Section: Other Forms Of Insulin Degludec For T2dm Patientssupporting

confidence: 59%

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes

Thuillier¹,

Alavi²,

Kerlan³

2015

DMSO

View full text Add to dashboard Cite

Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at the same time each day to ensure optimal biological action and consistent glycemic control. According to the literature, IDeg provides glycemic control and nocturnal hypoglycemia reduction comparable with other long-acting analogs in type 2 diabetes mellitus. The risk of severe hypoglycemic episodes seems also to be reduced when using IDeg therapy; however, long-term follow-up is warranted for monitoring of possible but relatively infrequent adverse events. IDeg is also available in combination with aspart insulin and with liraglutide. The above preparations have been approved by the European Medicines Agency and other national health authorities. In 2012, the US Food and Drug Administration asked for a complementary study on IDeg-associated cardiovascular risk. Future prospective evaluation of large cohorts of patients with type 2 diabetes mellitus treated with IDeg, with long-term follow-up, can provide further relevant information on the safety of IDeg therapy.

show abstract

Section: Other Forms Of Insulin Degludec For T2dm Patientssupporting

confidence: 59%

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes

Thuillier¹,

Alavi²,

Kerlan³

2015

DMSO

View full text Add to dashboard Cite

show abstract

“…16 HbA1c reduction with IdegU200 was non-inferior to IDegU100. The proportion of patients with confirmed hypoglycaemic episodes as well as the overall confirmed hypoglycaemia rate was low and similar for both formulations (55% vs. 52% patients with 5.17 vs. 5 …”

Section: Idegu200 Vs Idegu100mentioning

confidence: 80%

Insulin U100, 200, 300 or 500?

Dashora

Castro

2016

Br J Diabetes

View full text Add to dashboard Cite

This article reviews the currently available information about insulin preparations in a concentration higher than 100 units/mL. These might be particularly useful in people with significant insulin resistance and high insulin requirement. U-200 insulin has low variability and lower (nocturnal) or similar risk of hypoglycaemia compared with U-100 insulin but is currently more expensive. U-300 glargine insulin has low variability, less weight gain and lower nocturnal hypoglycaemia in some studies in comparison to U-100 glargine. It is priced lower than U-100 glargine. U-500R insulin has been in use for some time worldwide but is not licensed in the UK. It also has low variability and lower cost per unit of insulin compared with U-100R. There is no specific delivery device and it has a higher risk of hypoglycaemia and weight gain. More insulins are in development (U-500 short-acting analogue [Fluorolog] and U-400 pre-mix like insulin BIOD-531, amongst others). Br J Diabetes 2016;16:10-15

show abstract

“…В пяти открытых контролируемых исследованиях [12][13][14][15] у пациентов с СД 2 типа (СД2) сравнивалось действие инсулина деглудек 100 Ед/мл и деглудек 200 Ед/мл (1 исследование) и инсулина гларгин 100 Ед/мл (4 исследования). У пациентов, находящихся на терапии базальным инсулином деглудек 200 Ед/мл, значения гликированного гемоглобина (HbA 1c ) значимо не отличались по сравнению с применением инсулина гларгин 100 Ед/мл, также не было отмечено существенной разницы в суммарной суточной дозе инсулинов и частоте гипогликемий.…”

Section: -4 фазы исследования: эффективность и безопасностьunclassified

Special aspects of concentrated insulins: basic characteristics and research findings

Demidova¹,

Balutina²

2020

Diabetes mellitus

View full text Add to dashboard Cite

The appearance of concentrated insulins in clinical practice determines the need to analyze product priorities in appropriate groups of patients with diabetes. The aim of this article is to summarize the literature on concentrated insulins (i.e. insulin lispro 200 units/mL, insulin degludec 200 units/mL, insulin glargine 300 units/mL) from randomized controlled trials, derive guidance on appropriate and safe use of these agents and demonstrate experience in real clinical practice. Severe hypoglycemia in all studies was generally low (though higher with prandial plus concentrated basal analogue therapy), and statistical improvements in other hypoglycemia categories were observed for concentrated basal insulins versus insulin glargine 100 units/mL. In all analyzed data hypoglycemic effect of insulin glargine 300 units/mL was equitable to insulin glargine 100 units/mL. Other important findings demonstrate more constant and prolonged insulin action with low within-subject/ between-day variability for insulin glargine 300 units/mL versus insulin glargine 100 units/mL, therefore, more physiological treatment might prevent from diabetic microvascular complications. The results of randomized trials are comparable with our clinical practice experience and indicate efficacious and safe glucose-lowering properties without risk of severe hypoglycemia.

show abstract

Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare)

Cited by 26 publications

References 13 publications

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes

Insulin U100, 200, 300 or 500?

Special aspects of concentrated insulins: basic characteristics and research findings

Contact Info

Product

Resources

About